EPP says EU needs Alzheimer’s plan with concrete measures and deadlines
We understand the burden that Alzheimer’s disease (AD) places on individuals, caregivers and societies, and have dedicated more than 30 years to advancing the science of this devastating disease. We continue to encourage the recognition of initial cognitive changes caused by AD and the need to arm clinicians with resources to support early and accurate diagnosis, and for policymakers to provide investment in services and access to new therapeutics that strike at the potential causes of disease.
By 2025, 9.1 million people will be living with dementia in the EU and MEPs must recognize that with an ageing population, this number will increase drastically. Projections by the umbrella organization Alzheimer Europe show that in 2050, that figure is set to rise to 14.3 million.
In this second article from an independent series supported by Lilly, Euractiv speaks with MEP Tomislav Sokol (EPP) and Alzheimer Europe as they call for Europe to put in place a concrete plan to address AD, supported by adequate funding.
EUCAR 2024-145
Tags in this Article:
Related articles
2023 Sustainability Report
Lilly unites caring with discovery to create medicines that make life better for people around the world. We strive to set measurable goals to track the progress and performance of our sustainability strategy. Our goals help drive accountability and are grounded in our purpose to create medicines that make life better.
Progress on Alzheimer’s Disease stagnating, warns Alzheimer Disease International CEO...
While stopping the progression of Alzheimer’s disease is not yet possible, hope is on the horizon in the form of new breakthroughs in diagnostics and new treatments. Yet scientific advances alone are not enough; public awareness, clinical practice and healthcare systems across the world must evolve in-step with scientific progress to drive confidence in what can now be achieved and deliver meaningful change for those affected.
Improving Early Detection and Diagnosis of Alzheimer’s disease
Research has undisputably shown that the key to preventing or delaying the cognitive decline associated with Alzheimer’s disease (AD) lies in early and accurate detection and diagnosis. Through this, patients can be provided with the opportunity to receive the right treatment at the right time. Not only can this improve their quality of life, but it has the potential to reduce long-term care costs associated with AD.